6505--RSV Vaccine

The Department of Veterans Affairs National Acquisition Center is procuring Respiratory Syncytial Virus (RSV) vaccines through a single award national contract. The solicitation seeks an FDA-approved RSV vaccine with a unique 11-digit National Drug Code (NDC) number from manufacturers maintaining FDA current Good Manufacturing Practices (cGMP) compliance. Offerors must submit detailed pricing information for various package sizes across a base year and four one-year option periods, including a mandatory 0.5% Cost Recovery Fee. The procurement covers an estimated annual usage of 248,803 units across VA, DoD, Indian Health Service, and Bureau of Prisons facilities. Proposals must be submitted electronically by July 1, 2025, at 2:30 PM CT, with the original solicitation issued on April 21, 2025.

This solicitation is set aside for small businesses under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) with a size standard of 1,300 employees. The contract will be distributed through Pharmaceutical Prime Vendor programs, including McKesson Corporation and other listed distributors. An important amendment issued on June 30, 2025, clarifies that while the awarded national contract product will be a mandatory source for adults, it will not be mandatory when clinically inappropriate, such as for patients outside the specified age range. The contract structure spans five years total with the base year plus four option years, serving multiple federal agencies and facilities nationwide. The procurement falls under PSC code 6505 for Drugs and Biologicals, reflecting the pharmaceutical nature of the requirement.